Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus EMEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus EMEND.
ANTIVERT vs EMEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Category C
Category C
Antiemetic
Antiemetic